Shares of Fresenius Medical Care AG & Co. KGaA (ETR:FME) have received an average recommendation of “Buy” from the twenty analysts that are currently covering the stock, MarketBeat.com reports. Nine analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is €82.75 ($96.22).
FME has been the subject of several research analyst reports. Credit Suisse Group set a €75.00 ($87.21) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research note on Wednesday, October 31st. Independent Research set a €72.00 ($83.72) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research note on Friday, December 7th. Nord/LB set a €72.00 ($83.72) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Friday, December 14th. JPMorgan Chase & Co. set a €83.20 ($96.74) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Wednesday, December 26th. Finally, UBS Group set a €82.00 ($95.35) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Wednesday, January 30th.
Get Fresenius Medical Care AG & Co. KGaA alerts:Shares of ETR:FME traded up €1.04 ($1.21) during mid-day trading on Friday, hitting €68.50 ($79.65). The company had a trading volume of 1,113,162 shares, compared to its average volume of 704,197. Fresenius Medical Care AG & Co. KGaA has a one year low of €75.53 ($87.83) and a one year high of €93.82 ($109.09).
Fresenius Medical Care AG & Co. KGaA Company Profile
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
See Also: What do I need to know about analyst ratings?
No comments:
Post a Comment